Table 1

Participant demographics

CharacteristicsParticipants
PAHCTEPHAll
(n=25)(n=49)(n=74)
Age in years, mean (SD), range42.7 (14.6), 20–6961.5 (10.2), 41–8355.2 (14.8), 20–83
Sex, male/female n (%)7 (28.0)/18 (72.0)15 (30.6)/ 34 (69.4)22 (29.7)/ 52 (70.3)
WHO functional class, n (%)
 Class Ⅰ3 (12.0)13 (26.5)16 (21.6)
 Class Ⅱ22 (88.0)23 (46.9)45 (60.8)
 Class Ⅲ0 (0.0)13 (26.5)13 (17.6)
 Class Ⅳ0 (0.0)0 (0.0)0 (0.0)
Oxygen, n (%)
 All day7 (28.0)12 (24.5)19 (25.7)
 At night only2 (8.0)8 (16.3)10 (13.5)
 No oxygen16 (64.0)29 (59.2)45 (60.8)
Symptoms or side effects, n (%)
 Shortness of breath (symptom)9 (36.0)28 (57.1)37 (50.0)
 Side effects21 (84.0)5 (10.2)26 (35.1)
  Pain16 (64.0)5 (10.2)21 (28.4)
  Nausea6 (24.0)3 (6.1)9 (12.2)
  Diarrhoea10 (40.0)0 (0.0)10 (13.5)
Treatment, n (%)
 Only oral10 (40.0)25 (51.0)
 Intravenous8 (32.0)
 Subcutaneous6 (24.0)
 Inhalation1 (4.0)
 Post-BPA or ongoing BPA24 (49.0%)
Mean PAP, mm Hg (SD), range42.5 (12.3), 22–6730.1 (11.9), 16–6434.3 (13.3), 16–67
 Only oral39.0 (12.3), 22–6636.8 (11.4), 21–64
 Intravenous43.1 (13.3), 23–63
 Subcutaneous48.2 (11.7), 37–67
 Inhalation38.0(-), 38
 Post-BPA or ongoing BPA23.1 (7.6), 16–51
  • BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension; GAD-7, Generalised Anxiety Disorder 7-item questionnaire; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PHQ-9, 9-item Patient Health Questionnaire.